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Background: We observed a disproportional 18 F-fluorothymidine (F-FLT) uptake in follicular lymphoma (FL)
relative to its low cell proliferation. We tested the hypothesis that the ‘excess’ uptake of 18 F-FLT in FL is related to
error-prone DNA repair and investigated whether this also contributes to 18 F-FLT uptake in diffuse large B cell
lymphoma (DLBCL).
Methods: We performed immunohistochemical stainings to assess the pure DNA replication marker MIB-1 as well
as markers of both DNA replication and repair like PCNA, TK-1 and RPA1 on lymph node biopsies of 27 FLs and 35
DLBCLs. In 7 FL and 15 DLBCL patients, 18 F-FLT-PET had been performed.
Results: 18 F-FLT uptake was lower in FL than in DLBCL (median SUVmax 5.7 vs. 8.9, p = 0,004), but the ratio of
18 F-FLT-SUVmax to percentage of MIB-1 positive cells was significantly higher in FL compared with DLBCL
(p = 0.001). The median percentage of MIB-1 positive cells was 10% (range, 10% to 20%) in FL and 70% (40% to
80%) in DLBCL. In contrast, the median percentages of PCNA, TK-1 and RPA1 positive cells were 90% (range, 80 to
100), 90% (80 to 100) and 100% (80 to 100) in FL versus 90% (60 to 100), 90% (60 to 100) and 100% (80 to 100) in
DLBCL, respectively.
Conclusions: This is the first demonstration of a striking discordance between 18 F-FLT uptake in FL and tumour
cell proliferation. High expression of DNA replication and repair markers compared with the pure proliferation
marker MIB-1 in FL suggests that this discordance might be due to error-prone DNA repair. While DNA repair-
related 18 F-FLT uptake considerably contributes to 18 F-FLT uptake in FL, its contribution to 18 F-FLT uptake in
highly proliferative DLBCL is small. This apparently high contribution of DNA repair to the 18 F-FLT signal in FL may
hamper studies where 18 F-FLT is used to assess response to cytostatic therapy or to distinguish between FL and
transformed lymphoma.
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Positron emission tomography (PET) with 18 F-fluoro-
deoxyglucose (18 F-FDG) is widely used in (re)staging
and therapy monitoring of lymphoma. Uptake of 18
F-FDG in malignant cells is only partially related to pro-
liferation [1,2]. 18 F-fluorothymidine (18 F-FLT), a thy-
midine analogue, has been tested for its ability to more
specifically measured tumour proliferative activity [3].* Correspondence: m.wondergem@vumc.nl
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reproduction in any medium, provided the orig18 F-FLT uptake is determined by thymidine kinase-I
(TK-1) activity, an enzyme closely linked to DNA synthe-
sis and, hence, indirectly to tumour cell proliferation [4].
Non-Hodgkin’s lymphomas can have low and high pro-
liferative activity, e.g. indolent lymphomas such as low-
grade FL, and aggressive lymphomas, such as diffuse large
B cell lymphoma (DLBCL), respectively. Both can be im-
aged by PET, using either 18 F-FDG or 18 F-FLT. Previ-
ously, a close correlation was reported between 18 F-FLT
uptake and the proliferation fraction in a mixed popula-
tion of patients with FL and DLBCLs [5].is is an Open Access article distributed under the terms of the Creative
mmons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
inal work is properly cited.
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for the pure proliferation/replication marker Ki67, ex-
pectedly demonstrated a small percentage of positive
cells in FL and a high percentage in DLBCL. However,
when analyzing 18 F-FLT uptake in FL and DLBCLs, we
observed that uptake of 18 F-FLT is disproportional to
cellular proliferation in untreated FL; the uptake is much
higher than expected based on cellular proliferation
alone [6].
Since the uptake of thymidine is not only increased in
replicative DNA synthesis in proliferating cells but also
with enhanced DNA repair in quiescent cells, we now
aimed to test the hypothesis that the ‘excess’ uptake of
18 F-FLT in FL may be related to error-prone DNA re-
pair known to occur in FL and to be responsible for the
generation of somatic hypermutation (SHM) and class-
switch recombination (CSR). In addition, we investigated
whether this DNA repair contributes to 18 F-FLT up-
take in DLBCLs since SHM/CSR also occurs in most
DLBCLs.
Methods
Twenty-two patients with lymphoma (7 FL and 15
DLBCL) underwent whole-body 18 F-FLT-PET prior to
treatment in prospective clinical trials at VU University
Medical Center (NTR 4187(Dutch trial registry)) and
Technische Universität München (TUM Local ethics
committee nr 978/03) [7,8]. In these patients, paraffin
sections of lymph node biopsies obtained prior to im-
aging were retrieved for immunohistochemical staining.
In addition, at the University of Iowa Hospitals and
Clinics (UIHC), paraffin sections of 20 cases of FL and
20 cases of DLBCL presenting between 1990 and 2008
were randomly selected from the files of the Depart-
ment of Pathology. Diagnosis was revised according to
the WHO classification 2008. All biopsies had been ob-
tained prior to treatment for diagnostic reasons, and all
FL were grade I or II.
Immunohistochemistry
Immunohistochemistry on all samples was performed at
the Department of Pathology of UIHC. Sections of the
formalin-fixed, paraffin-embedded tissue were deparaf-
finized in xylene, rehydrated in graded alcohols and
rinsed. After antigen retrieval, endogenous peroxidase
activity was blocked using 3% H2O2. The sections were
then incubated with antibodies against Ki-67 (Clone
MIB-1, DakoCytomation; Carpinteria, CA, USA), which
is specific only for replicative DNA synthesis (prolifera-
tion) as well as for the replication and repair markers
proliferating cell nuclear antigen(PCNA) and replica-
tion protein A (RPA32/RPA2) (Abcam Inc., Cambridge,
MA, USA), and TK1 (Clone F12, Novus Biologicals,
Inc., Littleton, CO, USA), for 30 to 60 min at roomtemperature. For the detection of bound antibodies,
the EnVision technique (DakoCytomation; Carpinteria,
CA, USA) with diaminobenzidine as a substrate was
used. The percentage of cells positive for nuclear ex-
pression of MIB-1, PCNA, RPA32/RPA2 and TK1 in
follicles and diffuse areas were counted in 5 × 400 random
fields and an average was calculated [9]. To include DNA
synthesis for both proliferation and repair, all positive cells
were counted independent of staining intensity for both
PCNA and TK-1 [9].
18 F-FLT PET
At VUMC, PET imaging was done using a full ring
PET-CT scanner (Philips Gemini TF64). Acquisitions
(3 min/bed) started approximately 60 min after about
185 MBq 18 F-FLT iv, covering a skull mid-thigh tra-
jectory. At TUM, a full ring PET scanner (ECAT HR+,
Siemens/CTI) was used, acquisition starting 45 min after
approximately 300 MBq 18 F-FLT iv. Circular regions of
interest were drawn semi-automatically containing the
area of increased 18 F-FLT uptake to calculate standar-
dized uptake values (SUV) as described before [7,10]. Ma-
ximum values of 18 F-FLT-SUV were calculated for all
biopsied lesions, all larger than 3 cc, minimizing partial
volume effects.
Statistics
18 F-FLT SUVmax and the 18 F-FLT SUVmax to
MIB-1 ratio were compared using the Mann–Whitney
U test. Correlation coefficients were calculated using
the Spearman’s rho test. Differences were considered
significant at a level of p < 0.05. The model was fitted
using linear regression analysis.
Results
In the 22 patients who underwent 18 F-FLT imaging,
18 F-FLT uptake was lower in FL than in DLBCL (median
SUVmax 5.7 (range 3.0 to 6.7) versus 8.9 (range 3.7 to 18;
p = 0.004)), consistent with the lower proliferation rate of
FL compared with DLBCL (median percentage of MIB-1
positive cells 10% in the 7 FL patients and 70% in the 15
DLBCL patients (Table 1)). However, in FL 18 F-FLT-
SUVmax relative to tumour, cell proliferation was dispro-
portionally high compared to that of the DLBCL patients
(mean ratio of 0.38 for FL vs. 0.14 for DLBCL, p = 0.001)
(Table 1). While the median SUVmax of FL was 64% of
that in DLBCL, the median percentage ofMIB-1 positive
cells of FL was only 14% of that in DLBCL.
In order to determine whether the disproportional in-
crease of 18 F-FLT uptake in FL relative to its low cell
proliferation might be related to error-prone DNA repair
known to occur in FL, we stained tumour samples of the
22 patients for the DNA replication and repair markers
PCNA, TK-1 and RPA1 in addition to the pure DNA
Table 1 Immunohistochemical values and 18 F-FLT uptake (SUV max) for all patients who underwent PET scanning
and biopsy
Lymphomatype MIB1 (%) PCNA (%) TK1 (%) RPA (%) 18 F-FLT (SUVmax) 18 F-FLT/MIB ratio
1 Follicular 10 100 70 80 6.2 0.62
2 Follicular 15 100 80 100 3.6 0.24
3 Follicular 20 90 80 100 3.0 0.15
4 Follicular 10 80 100 100 4.7 0.47
5 Follicular 20 80 100 ND 6.7 0.34
6 Follicular 20 80 100 100 6.5 0.33
7 Follicular 10 95 ND ND 5.7 0.57
8 Transformed 70 100 80 100 8.1 0.11
9 Transformed 50 100 90 100 5.4 0.11
10 Transformed 80 80 100 80 9.8 0.12
11 Transformed 70 70 80 100 6.1 0.08
12 Transformed 80 90 100 100 14.5 0.18
13 DLBCL 60 90 90 ND 10.5 0.18
14 DLBCL 70 70 60 ND 8.4 0.12
15 DLBCL 60 60 80 ND 9.8 0.16
16 DLBCL 80 70 90 ND 18.0 0.23
17 DLBCL 60 90 90 ND 8.9 0.15
18 DLBCL 40 60 90 ND 3.7 0.09
19 DLBCL 70 90 100 ND 7.2 0.10
20 DLBCL 70 90 100 ND 13.3 0.19
21 DLBCL 40 90 70 ND 8.4 0.21
22 DLBCL 80 80 80 ND 9.6 0.12
ND, not done.
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dian percentage of MIB-1 positive cells was 10% (range,
10% to 20%) in FL and 70% (40% to 80%) in DLBCL. In
contrast, the median percentages of PCNA, TK-1 and
RPA1 positive cells were 90% (range, 80 to 100), 90% (80
to 100) and 100% (80 to 100) in FL versus 90% (60 to
100), 90% (60 to 100) and 100% (80 to 100) in DLBCL,
respectively.
The immunostaining results of the two patient groups
with and without 18 F-FLT PET (22 and 40 (20 FL and
20 DLBCL), respectively) were very similar (Table 2);
again in the group without 18 F-FLT PET, the median
percentage of MIB-1 positive cells was 10% (range, 5%
to 30%) in FL and 80% (60%to 90%) in DLBCL. And
also, the median percentage PCNA, TK-1 and RPA posi-
tive cells were 90% (range 80 to 100), 95% (90 to 100)
and 100% in FL versus 100% (80 to 100), 95% (70 to
100) and 100% in DLBCL, respectively.
Both in FL and DLBCL, PCNA and TK-1 showed a
characteristic staining pattern with 3+ or 4+ in proli-
ferating cells and 1+ to 2+ staining of quiescent cells
(Figure 1). The intensity of PCNA, TK-1 and RPA1staining in quiescent or proliferating cells was similar in
FL and DLBCL.
There was a statistically significant positive correlation
between 18 F-FLT uptake and the percentage of MIB-1
positive cells for DLBCL (r = 0.55, p = 0.03) but not for
FL (r = 0.15, p = 0.74; Figure 2).
We found no significant correlation between FLT up-
take and%TK-1 positive cells when cell staining for TK1
was considered positive regardless of staining intensity
(r = 0.44, p = 0.18). Only if those cells with 3+ or 4+
staining intensity were considered positive (i.e. the pro-
liferating cells, which are the same cells that are MIB-1
positive), was there a significant correlation, mirroring the
correlation between FLT uptake and MIB-1 expression.
Discussion
The unexpected high uptake of 18 F-FLT in FL relative
to its cell proliferation reflected by the higher 18 F-FLT-
SUVmax to MIB-1 ratio in FL compared to DLBCL is
in line with a previous study, where the ratio of 3H-
thymidine uptake to percentage of MIB-1-positive cells
in FL was 1.5 times that in DLBCL, associated with
Table 2 Immunohistochemical values for all patients with biopsy material only
Follicular DLBCL
MIB1 (%) PCNA (%) TK1 (%) RPA (%) MIB1 (%) PCNA (%) TK1 (%) RPA (%)
1 5 90 95 ND 80 100 100 100
2 20 90 95 100 80 100 80 100
3 10 100 95 100 80 100 70 100
4 10 100 95 ND 60 100 100 100
5 10 90 90 ND 80 100 95 100
6 10 80 100 100 80 100 95 100
7 10 90 95 100 60 80 95 100
8 10 100 90 100 70 100 100 ND
9 20 90 95 100 80 100 90 ND
10 20 90 90 ND 60 80 90 100
11 10 100 100 100 60 80 70 ND
12 10 90 95 ND 90 100 100 100
13 10 90 95 ND 90 100 100 100
14 10 100 100 100 80 90 95 100
15 10 100 95 ND 80 100 90 100
16 20 100 95 ND 90 100 95 100
17 5 90 100 100 60 90 95 100
18 10 90 95 100 90 100 80 ND
19 30 80 90 100 70 100 100 100
20 10 100 95 ND 70 100 100 100
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(PCNA) [11]. The disproportionally high expression of
DNA replication and repair markers (TK-1, PCNA,
RPA) compared with the specific replication marker
MIB-1 suggests that the increase of 18 F-FLT uptake inFigure 1 H and E, MIB-1, TK-1, PCNA and RPA staining in an untreate
PCNA- and RPA-positive cells is 5%, 100%, 90%, and 100%, respectively. No
staining of bystander mantle zone cells.FL might be due to DNA repair in quiescent (and prolif-
erating) FL cells involved in error-prone DNA repair
known to occur in the germinal centres of FL. This
error-prone repair is responsible for generation of SHM
and CSR, which constitute one of the bases for ourd patient with grade 1 FL. Estimated percentage ofMIB-1, TK-1,
te the specific TK-1 staining of germinal centre cells with lack of TK-1
Figure 2 Correlation between 18 F-FLT uptake and percentage
MIB-1 positive cells. Absent correlation between 18 F-FLT uptake
and the percentage of MIB-1 positive cells in FL (r = 0.15, p = 0.74)
and a significant correlation in DLBCL and transformed lymphoma
(r = 0.55, p = 0.03).
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been reported to play a role in SHM/CSR [11]. The
hypothesis that DNA repair might contribute to total
18 F-FLT uptake can be supported by observations in
animal models; De Saint-Hubert et al. showed an ac-
cumulation of cells in S-phase 2days after cyclophos-
phamide treatment of mice with Burkitt’s lymphoma,
suggesting repair of the chemotherapy-induced DNA
cross-links, accompanied by a later decrease of 18 F-FLT
uptake, at 7 days posttreatment [12].
We found high percentages of positive cells for both
FL and DLBCL when looking at PCNA, TK-1 and RPA1,
all known to be involved in both DNA replication and
repair [13,14]. Others also found high levels of PCNA
positivity in DLBCLs [15] and similar levels of TK-1 ac-
tivity in low- and high-grade lymphoma [16]. Chang
et al. show high PCNA positivity in FLs with positivity
in both follicular and interfollicular areas without speci-
fying the staining intensity [17]. The characteristic stain-
ing pattern of PCNA and TK-1 seen in both FL andDLBCL with 3+ or 4+ in proliferating (i.e. MIB-1 posi-
tive) cells and 1+ to 2+ staining of quiescent cells is ex-
plained by the fact that both PCNA and TK-1 show a
striking increase in the expression during S-phase but
are also expressed albeit to a lesser extent in other
phases of the cell cycle [13,18]. In fact, PCNA can be de-
tected at higher levels in all phases of the cell cycle after
cell damage by radiation, suggesting DNA repair [13,19].
High expression of DNA replication and repair markers
(TK-1, PCNA, RPA) in FL was not only observed in the
7 FL patients who underwent 18 F-FLT PET but was
confirmed in an additional 20 patients with FL in whom
only immunohistochemical studies were performed. The
same staining intensity and pattern observed in the 15
patients with DLBCL who underwent FLT-PET imaging
was confirmed in the additional 20 DLBCL patients with
immunohistochemical studies only.
To illustrate the potential relative contribution of
DNA repair synthesis to 18 F-FLT uptake in FL and
DLBCL, a model was fitted using linear regression on
the data depicted in Table 1. Since the FLT uptake es-
sentially reflects the TK1 activity, in this model, we as-
sumed the TK-1 activity per repairing quiescent cell to
be a third of that in a proliferating cell, compatible with
the 1+ to 2+ versus 3+ to 4+ staining intensity of quies-
cent versus proliferating cells.
SUVmax ¼ −1:4þ 0:15%proliferating cellsð Þ
þ 0:05%quiescentcellsð Þ
% proliferating cells = %MIB −1 positive cells.
% quiescent cells = % TK-1 positive cells −%MIB-1 po-
sitive cells.
The model assumes that TK-1 activity per proliferating
cell is similar in FL and DLBCL. Since no difference in
S-phase duration between FL and DLBCL is reported
and DNA synthesis rate (and hence TK-1 activity) is pro-
portional to S-phase duration, this assumption seems
valid [20]. R-square is 0.51, indicating a moderate fit, an
interesting result considering the relatively small number
of patients who underwent PET scans with FLT.
While SHM/CSR also occurs in most DLBCLs (ex-
plaining the discordance between percentage of MIB-1-
positive and TK-1-positive cells in most DLBCL in our
study), the relative contribution of DNA repair to 18
F-FLT uptake in DLBCL is apparently small in most
cases, so that a significant correlation between percent-
age of MIB-1-positive cells and 18 F-FLT uptake can be
found. The absence of this correlation in FL might be
due to the increased DNA repair, interfering with the
correlation, or the small number of samples. Conse-
quently, this should be confirmed in a larger sample,
also including higher grade FLs, with possible higher
MIB-1 percentages.
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and a FL is the presence of a microenvironment in FL.
To determine the percentage positive cells for every im-
munohistochemical marker, we counted larger areas of
the FL, including both the lymphoma cells and the
microenvironment. It reflects the fact that 18-FLT up-
take in the whole lymph node is caused by uptake in
both lymphoma- and microenvironmental cells. This
‘average expression’ method was reported by Chalkidou
et al. to give the best results for correlation of prolife-
ration markers and 18 F-FLT uptake [21]. However, we
cannot determine which proportion of the uptake of
18 F-FLT in FL (caused by proliferation or repair) is ex-
plained by uptake in the microenvironmental cells. The fact
that the composition of the microenvironment can vary
considerably in its proportions of T cells, macrophages and
follicular dendritic cells between FLs, all with different un-
known contributions to total 18 F-FLT uptake is an add-
itional complicating factor in hypothesis generation [17].
Imaging with PET has been used in an attempt to dis-
tinguish indolent from transformed lymphoma. Since
18 F-FDG PET scans have shown considerable overlap
in SUV between FL and transformed lymphoma, and
since the main characteristic of transformation is in-
creased proliferation, imaging with 18 F-FLT was also in-
vestigated. Unexpectedly, 18 F-FLT showed similar
overlap as 18 F-FDG in SUV of FL and transformed
lymphoma [22-25]. In our FL and transformed lymph-
oma patients, we also found overlap; SUVmax in FL was
3.0 to 6.7, in transformed lymphoma 5.4 to 14.5. This
might, at least in part, be explained by our findings of
additional DNA repair-related 18 F-FLT uptake in non-
proliferating FL cells or the microenvironment.
18 F-FLT has also been used to image a decrease in
proliferation following effective cytostatic therapy, thus
predicting response [8,26]. However, if 18 F-FLT also im-
ages DNA repair in addition to proliferation in FL, the
change in 18 F-FLT uptake following FL treatment will
be confounded by the high contribution of DNA repair
and, hence, significant changes in cellular proliferation
may be missed or obscured. For example, if the pretreat-
ment FL SUVmax is 5.0 with only 1.0 SUV unit related
to proliferation with the remaining 4.0 SUV units ac-
tually related to repair, a 50% decrease in proliferation
without any change in DNA repair will change the SUV
from 5.0 to only 4.5, an insignificant change erroneously
indicating lack of anti-proliferative effect. Cytotoxic ther-
apy might even enhance DNA repair. Fortunately, it ap-
pears that the increased 18 F-FLT uptake that is due to
increased DNA repair following cytotoxic therapy (i.e.,
gemcitabine) is only transient, subsiding within 48 h
after dose administration, although this phenomenon
has been described to be dependent on the cytostatic
drugs that are used [27,28]. Following cytostatic therapy,accumulation of cells in S phase has been described,
increasing 18 F-FLT uptake [12,29]. Thus, delaying 18
F-FLT imaging by at least 48 h or more after treatment
to assess response (depending on the cytostatic agent
and its mechanism of action) may be sufficient to over-
come this part of the problem. However, further re-
search is needed to validate this hypothesis.
Conclusions
To our knowledge, this is the first demonstration of a strik-
ing discordance between 18 F-FLT uptake in FL and
tumour cell proliferation. Our immunohistochemical find-
ing of high expression of DNA replication and repair
markers in FL suggests that the disproportional increase
of 18 F-FLT uptake might be due to error-prone DNA
repair, responsible for SHM/CSR in FL cells or the mi-
croenvironment. This may hamper studies where 18 F-FLT
is used for assessing response to cytostatic therapy or to
distinguish between FL and transformed lymphoma. Fur-
ther research is needed to elucidate the mechanism of 18-
F-FLT uptake to be able to accurately interpret changes in
uptake following therapy or histologic transformation.
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